Cogent Biosciences Reports Updated Lead-In Data From Ongoing Phase 3 PEAK Trial At ASCO Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Cogent Biosciences has reported updated lead-in data from its ongoing Phase 3 PEAK trial at the ASCO Annual Meeting. The company has accelerated its guidance for the PEAK Phase 3 trial, with enrollment completion now expected in the third quarter of 2024.
May 23, 2024 | 9:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cogent Biosciences has provided an update on its Phase 3 PEAK trial, accelerating the expected enrollment completion to Q3 2024. This could positively impact investor sentiment and the stock price in the short term.
The acceleration of the PEAK Phase 3 trial enrollment completion is a significant milestone for Cogent Biosciences. This update is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100